Literature DB >> 3792231

Diabetic neuropathy. Human and experimental.

P K Thomas.   

Abstract

Human diabetic neuropathy consists of various clinical syndromes and it is unlikely that any single aetiological process is responsible for all of them. There is probably a complex interaction of different metabolic factors, microvascular disease, and perhaps even a genetic predisposition and other as yet unidentified environmental factors. Abnormalities of sorbitol and myo-inositol metabolism have been described in animal models and human studies of neuropathy and must be regarded as of major importance, especially since they can be profoundly influenced by blocking the enzyme aldose reductase. However, a comparison of the abnormalities in the peripheral nervous system of animals with diabetes and in human diabetic neuropathy shows that the clinical and pathological resemblances are not close. Therefore, caution is needed when using the results of animal studies to interpret the manifestations of diabetic neuropathy in man.

Entities:  

Mesh:

Year:  1986        PMID: 3792231     DOI: 10.2165/00003495-198600322-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  22 in total

1.  Vibratory perception in diabetics during arrested blood flow to the limb.

Authors:  I STEINESS
Journal:  Acta Med Scand       Date:  1959-03-04

2.  Probability of conduction deficit as related to fiber length in random-distribution models of peripheral neuropathies.

Authors:  S G Waxman; M H Brill; N Geschwind; T D Sabin; J Y Lettvin
Journal:  J Neurol Sci       Date:  1976-09       Impact factor: 3.181

3.  Improvement in nerve conduction following treatment in newly diagnosed diabetics.

Authors:  J D Ward; C G Barnes; D J Fisher; J D Jessop; R W Baker
Journal:  Lancet       Date:  1971-02-27       Impact factor: 79.321

4.  The effects of hypoxia on the excitability of the isolated peripheral nerves of alloxan-diabetic rats.

Authors:  K N Seneviratne; O A Peiris
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-10       Impact factor: 10.154

5.  Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.

Authors:  J H Mayer; D R Tomlinson
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

6.  Proximal diabetic neuropathy.

Authors:  A K Asbury
Journal:  Ann Neurol       Date:  1977-09       Impact factor: 10.422

7.  Decreased axonal transport of structural proteins in streptozotocin diabetic rats.

Authors:  J Jakobsen; P Sidenius
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

8.  Distal neuropathy in experimental diabetes mellitus.

Authors:  M J Brown; A J Sumner; D A Greene; S M Diamond; A K Asbury
Journal:  Ann Neurol       Date:  1980-08       Impact factor: 10.422

9.  Degenerative neuropathy in insulin-treated diabetic rats.

Authors:  S G Westfall; D L Felten; J A Mandelbaum; S A Moore; R G Peterson
Journal:  J Neurol Sci       Date:  1983-09       Impact factor: 3.181

10.  Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy.

Authors:  P J Dyck; J L Karnes; J Daube; P O'Brien; F J Service
Journal:  Brain       Date:  1985-12       Impact factor: 13.501

View more
  1 in total

1.  Biochemical effects of irbesartan in experimental diabetic nephropathy.

Authors:  Richa Vaishya; J Singh; Harbans Lal
Journal:  Indian J Pharmacol       Date:  2009-12       Impact factor: 1.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.